

Clinical Quality Measures

2023 measurement year

| Measure | | Rating | Rate |
|---|-------------------------|--------|------|
| Adolescent Depression | PHQ-9 Utilization* | - | - |
| | Follow-up at Six Months | - | - |
| | Response at Six Months | - | - |
| | Remission at Six Months | - | - |
| | Follow-up at 12 Months | - | - |
| | Response at 12 Months | - | - |
| | Remission at 12 Months | - | - |
| Adult Depression | PHQ-9 Utilization* | - | - |
| | Follow-up at Six Months | - | - |
| | Response at Six Months | - | - |
| | Remission at Six Months | - | - |
| | Follow-up at 12 Months | - | - |
| | Response at 12 Months | - | - |
| | Remission at 12 Months | - | - |
| Adolescent Mental Health and/or Depression Screening* | | - | - |
| Colorectal Cancer Screening | | - | - |
| Optimal Asthma Control - Adults | | - | - |
| Optimal Asthma Control - Children | | - | - |
| Optimal Diabetes Care | | - | - |
| HbA1c Control | | - | - |
| BP Control | | - | - |
| Daily Aspirin Use | | - | - |
| Statin Use | | - | - |
| Tobacco-Free | | - | - |
| Optimal Vascular Care | | - | - |
| BP Control | | - | - |
| Daily Aspirin Use | | - | - |
| Statin Use | | - | - |
| Tobacco-Free | | - | - |

- Medical group not assigned to measure, did not have results, or did not meet reporting threshold

*Measure not risk adjusted

Avera Medical Group - MARSHALL

Healthcare Effectiveness Data and Information Set (HEDIS) Measures

2023 measurement year

| Measure | Rating | Rate |
|---|---------|--------|
| Avoidance of Antibiotic Treatment in Acute Bronchitis/Bronchiolitis | Average | 77.30% |
| Breast Cancer Screening | Average | 81.80% |
| Cervical Cancer Screening | - | - |
| Childhood Immunization Status (Combo 10) | Average | 55.80% |
| Chlamydia Screening in Women | Below | 24.60% |
| Controlling High Blood Pressure | Average | 77.90% |
| Diabetes Eye Exam | Below | 56.50% |
| Immunizations for Adolescents (Combo 2) | Average | 34.30% |
| Follow-up Care for Children Prescribed ADHD Medication | - | - |
| Osteoporosis Management in Women Who Had a Fracture | - | - |
| Use of Spirometry Testing in the Assessment and Diagnosis of COPD | - | - |

- Medical group not assigned to measure, did not have results, or did not meet reporting threshold

Ratings

Above: Medical group's actual rate is significantly above its expected rate (for risk adjusted measures) or the statewide/medical group rate (for unadjusted/HEDIS measures).

Average: Medical group's actual rate is not statistically different than its expected rate (for risk adjusted measures) or the statewide/medical group rate (for unadjusted/HEDIS measures).

Below: Medical group's actual rate is significantly below its expected rate (for risk adjusted measures) or the statewide/medical group rate (for unadjusted/HEDIS measures).

Total Cost of Care

2023 measurement year

| Population | Monthly Average Cost | Rating | Higher/Lower than Average |
|------------|----------------------|--------|---------------------------|
| Overall | - | - | - |
| Adults | - | - | - |
| Pediatric | - | - | - |